Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer.

Gemcitabine-resistant pancreatic cancer cells develop a dependency on the mevalonate biosynthesis pathway, making them highly sensitive to statin treatment.

• Why it matters: Understanding metabolic adaptations in gemcitabine resistance is crucial because resistance limits therapy effectiveness in pancreatic ductal adenocarcinoma (PDAC). Identifying vulnerabilities could improve treatment strategies.
• What they did: Researchers generated gemcitabine-resistant PDAC models, evaluated pyrimidine metabolism and sensitivity to pathway inhibition, and analyzed HMGCR expression in clinical samples, using metabolite rescue experiments and mouse models.
• The result: Resistance causes suppression of pyrimidine salvage and creates a dependency on mevalonate biosynthesis, with low HMGCR expression predicting poor response; statins effectively inhibit resistant tumor growth, highlighting a potential therapeutic target.